Helicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.

Similar documents
Treatment of Helicobacter pylori Infection

ACG Clinical Guideline: Treatment of Helicobacter pylori Infection

Treating H. pylori in 2016

GASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師

Peptic Ulcer Disease Update

Disclosures. Co-founder and Chief Science Officer, TechLab

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?

Index. Note: Page numbers of article titles are in boldface type.

PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School

Peptic ulcer disease Disorders of the esophagus

Corporate Medical Policy

Management of Dyspepsia

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009

Prevpac Pylera Omeclamox-Pak

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe

EDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011

American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

High use of maintenance therapy after triple therapy regimes in Ireland

What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated

Gastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D

I. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection

Low Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial

National Digestive Diseases Information Clearinghouse

HELICOBACTER PYLORI UPDATE

QUICK QUERIES. Topical Questions, Sound Answers

Management of dyspepsia and of Helicobacter pylori infection

Helicobacter and gastritis

Sequioa Education Systems, Inc. 1

Gilles Jequier. Commercial Director Organobalance, a Novozymes Company

Efficacy of standard triple therapy versus bismuth-based quadruple therapy for eradication of Helicobacter Pylori infection

Copy right protected Page 1

Peptic Ulcer Disease and NSAIDs

Drug Class Monograph

Clinical Study Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Helicobacter pylori:an Emerging Pathogen

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin

Helicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease

TECHNOLOGY OVERVIEW: PHARMACEUTICALS

- Ali Yaghi. - Sara Yaghi. - Alia Shatnawi. 1 P a g e

Helicobacter pylori eradication an update on the latest therapies

Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection

Urea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013

Study population The study population comprised hypothetical patients with gastric and duodenal ulcer.

Treatment and Screening of H. pylori Infection in Alaskan Populations

Proton Pump Inhibitors (PPIs) (Sherwood Employer Group)

One-third of adults experience pain or discomfort in

Clinical Policy Title: Noninvasive testing for H. pylori

Clinical Policy Title: Noninvasive testing for H. pylori

Epidemiology of Peptic Ulcer Disease

Heartburn, also referred to acid reflux, happens when stomach acid flows back (refluxes) into your esophagus.

02 MAR 16 Page 1 of 29. Prevention of Helicobacter pylori infection

Helicobacter Connections. Barry Marshall

GI update. Common conditions and concerns my patients frequently asked about

Original article J Bas Res Med Sci 2015; 2(4):45-50.

Fecoprevalence and determinants of Helicobacter pylor infection among asymptomatic children in Myanmar

Helicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens

The Nobel Prize in Physiology or Medicine for 2005

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

Omeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.

Fecal incontinence causes 196 epidemiology 8 treatment 196

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

Clinical Policy Title: Breath Testing for H. Pylori

Stomach Pain Evidence-Based Methods in the Diagnosis and Treatment of Dyspepsia

Indications, diagnostic tests and Helicobacter pylori eradication

Bleeds in Cardiovascular Disease

Guidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee

HELICOBACTER PYLORI ERADICATION TREATMENT AND THE RISK OF GASTRIC AND OESOPHAGEAL CANCER

Health technology The use of four different combined treatments for Helicobacter pylori (H. pylori) infection. These were:

Second term/

Case 4: Peptic Ulcer Disease. Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie

Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis.

New Therapeutics Approach in gastroenterology. Abou Rached Antoine, MD, MBAIP

ÐÑÏÓÊÅÊËÇÌÅÍÅÓ ÎÅÍÏÃËÙÓÓÅÓ ÁÍÁÊÏÉÍÙÓÅÉÓ ÅËËÇÍÙÍ ÅÑÅÕÍÇÔÙÍ

Setting The setting was secondary care. The economic study was carried out in Hong Kong, China.

National Digestive Diseases Information Clearinghouse

Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W

Drugs Affecting the Gastrointestinal System. Antacids, Constipation, Increasing gastrointestinal motility

Clinical Policy Title: Noninvasive testing for H. pylori

Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network metaanalysis

Perspectives from Viet Nam

Rpts. GENERAL General Schedule (Code GE)

6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other

Setting The setting was community. The economic study was carried out in the USA.

Gastritis General standpoints

Abdominal Pain in a Young Aviator

Clinical Trial of Efcid (Himcocid) in Patients of Acid Peptic Disease

Chapter 63 Drugs Used in the Treatment of Gastrointestinal Diseases

SELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY

Management of Helicobacter pylori infectiondthe Maastricht IV/ Florence Consensus Report

Transcription:

An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology of Helicobacter pylori (H. pylori) Explain the significance of H. pylori in the etiology and pathophysiology of peptic ulcer disease Discuss diagnostic tests for H. pylori Compare and contrast therapeutic strategies employed in H. pylori treatment 1

Epidemiology One of the most common worldwide human infections Higher prevalence in developing countries Acquisition occurs during early childhood Current rates are decreasing Helicobacter 2008;13:1-6. Am J Gastroent 2007;102:1808-25. Am J of Med 2004;117:31-35. Risk Factors for Infection in Childhood Infected family member Having > 2 siblings Crowded living conditions Lower socioeconomic status Attendance at a daycare facility BMJ 2008;337:746-50. Am J of Med 2004;117:31-35. 2

Mode of Transmission Fecal oral Oral oral Gastric oral Helicobacter 1996;1:175-82. H. pylori and Peptic Ulcer Disease (PUD) Once thought microorganisms could not survive in acidic environment of stomach Association between H. pylori & PUD Most patients with PUD who are NOT taking NSAIDs have H. pylori Eradication of H. pylori ulcer recurrence Few patients with H. pylori develop PUD Helicobacter 2008;13:23-7. 3

H. pylori Self-Preservation Morphology Gram-negative Spiral-shaped Acid labile Virulence Factors Flagella Adherence pedestals Urease Urea NH 3 + CO 2 +NaOH Dipiro. 6 th ed Pathophysiology H. pylori ph & adhesion Stomach lining Ulceration Damage Cytokines 4

Pathophysiology Normal Gastric Mucosa Acute Gastritis Acquisition of H. pylori Asymptomatic or Symptomatic Acquisition Chronic Gastritis Duodenitis Duodenal Ulcer Gastric Ulcer Atrophic Gastritis Intestinal Metaplasia Gastric Cancer Dipiro. 6 th ed Types of Peptic Ulcers Duodenal Ulcer Gastric Ulcer 5

H. pylori Diagnosis Multiple tests can be used for H. pylori diagnosis Testing should only be performed if the clinician plans to treat Choice of diagnostic test depends ds on: Use of upper endoscopy Strengths/weaknesses of each test Cost of each test Am J Gastroent 2007;102:1808-25. Test Histology Rapid urease test Culture H. pylori Endoscopic Tests Description Considered gold standard where biopsy is examined by a pathologist Identifies active H. pylori infection via the organism s urease activity Sample is cultured to determine presence of H. pylori Advantages Good sensitivity and specificity (S & S) Inexpensive Good S & S in selected pts Antibiotic sensitivities Great specificity Disadvantages Expensive Trained personnel Sensitivity post tx. Expensive Difficult to perform availability 6

H. pylori Non-Endoscopic Tests Test Antibody detection Urea breath test (UBT) Fecal antigen test Description Detects antibodies to H. pylori Urease breaks down ingested labeled C-urea; pt exhales CO 2 Detects H. pylori antigen using polyclonal or monoclonal antibody in stool Advantages Inexpensive Widely available Identifies active infxn. Useful before and after tx. Identifies active infxn. Useful before and after tx. Disadvantages Not recommended after tx. Inconsistent reimbursement and availability Unpleasantness Polyclonal test less validated than UBT Am J Gastroent 2007;102:1808-25. To Treat Or Not To Treat? Treat Active PUD Confirmed history of PUD Gastric history of mucosa associated lymphoid tissue lymphoma (MALT) After endoscopic resection of gastric cancer Do Not Treat Non-ulcer dyspepsia Gastroesophageal reflux disease Persons using NSAIDs Am J Gastroent 2007;102:1808-25. 7

Eradication Absence of the microorganism at least 4 weeks after cessation of therapy Results in: Ulcer healing risk of recurrence to < 10% in 1 year risk of ulcer complications Urea breath test or fecal antigen test BMJ 2008;337:746-50. Factors to Consider. Efficacy Tolerability Drug interaction potential Likelihood of compliance Antibiotic resistance Cost BMJ 2008;337:746-50. Am J of Gastroent 2007;102:1808-25. 8

Drug Strategies Antisecretory agents Proton pump inhibitors (PPI), H 2 blockers (H 2 B) Enhance symptom relief Promote ulcer healing Antibiotics Penicillin, macrolides, tetracycline, metronidazole Bacteriostatic or bacteriocidal to H. pylori Bismuth: exact mechanism unknown BMJ 2008;337:746-50. Am J of Gastroent 2007;102:1808-25. Drug Strategies - Traditional Three-Drug Strategies 2 antibiotics + PPI Good efficacy More expensive adverse effects Good compliance Four-Drug Strategies 2 antibiotics + PPI + bismuth Good efficacy Least expensive regimen adverse effects compliance BMJ 2008;337:746-50. Helicobacter 2008;13:35-40. Am J of Gastroent 2007;102:1808-25. 9

Drug Strategies - Sequential Therapy Not widely used currently Has shown considerable efficacy Two five-day courses of therapy administered in succession PPI + amoxicillin followed by PPI + clarithromycin + metronidazole Am J of Gastroent 2007;102:1808-25. Three-Drug Regimens Drug Clarithromycin Amoxicillin PPI Clarithromycin Metronidazole PPI Amoxicillin Metronidazole PPI Dose 500mg bid 1gm bid bid 500mg bid 500mg bid bid 1gm bid 500mg bid bid Duration 10 14d 10 14d 10 14d Efficacy Excellent Excellent Good 10

Four-Drug Regimens Drug Bismuth Metronidazole Tetracycline PPI or H 2 B Bismuth Metronidazole Clarithromycin PPI or H 2 B Dose 525mg qid 250mg qid 500mg qid As directed 525mg qid 250mg qid 500mg qid As directed Duration 14d 14d Efficacy Excellent Excellent Antisecretory Agents Drug Cimetidine Famotidine Nizatidine Ranitidine Omeprazole Lansoprazole Pantoprazole Esomeprazole Healing 300 qid, 400 bid 20 bid 150 bid, 300 qhs 150 bid, 300 qhs 20 bid 30 bid 40 bid 20 bid Maintenance 400 800 qhs 20 40 qhs 150 300 qhs 150 300 qhs 20 40 qd 15 30 qd 40 qd 20 40 qd 11

Drug Substitution Do NOT substitute Ampicillin for amoxicillin Doxycycline for tetracycline Azithromycin for clarithromycin Administration Antibiotics: with meals Tetracycline: avoid administration with dairy products Metronidazole: avoid ethanol use Bismuth: with meals PPIs: 30 minutes prior to meals H 2 B: no administration issues 12

Adverse Effects Antibiotics General Drug Metronidazole Clarithromycin Tetracycline Amoxicillin Adverse Effect Diarrhea, abdominal pain Nausea, vomiting, candidiasis Disulfarim-like like reaction Metallic taste Abnormal taste Photosensitivity, rash Teeth discoloration Contraindicated < 8 years old Hypersensitivity reaction Adverse Effects Antisecretory Agents PPIs H 2 B Drug Adverse Effect Diarrhea, constipation, nausea Vomiting, headache Diarrhea, constipation, dizziness Bismuth salts Black discoloration stool/tongue Constipation, diarrhea, nausea Salicylate contraindicated in children with virus 13

Compliance Important factor for successful therapy Goal compliance = 80 90% of doses Decreases with: Multiple medications frequency of administration length of treatment Intolerable adverse effects Antimicrobial Resistance Emergence has lead to concern Occurs in 20% of cases Important determinant of successful eradication Minimal Resistance Amoxicillin Tetracycline Bismuth salts Increased Resistance Metronidazole Clarithromycin Alim Pharmacol Ther 2007;27:345-54. Gut 2004;53:1374-84. 14

Antimicrobial Resistance Metronidazole Most common Varies depending on antibiotic exposure 4 drug combo still efficacious i Clarithromycin Less common Greater effect on clinical outcome macrolide consumption is a risk factor Gut 2004;53:1374-84. Salvage Therapy Avoid antibiotics that have been used previously Bismuth-based quadruple therapy Levofloxacin triple therapy Levofloxacin 500 mg qd - bid Amoxicillin 1 gm bid PPI Am J Gastroent 2008;103:71-6. Am J Gastroent 2007;102:1808-25. Gastroent Clin N Am 2006;35:229-34. 15

Patient Case HPisa25y/o female who presents to the clinic with complaints of abdominal discomfort and a burning feeling. This had occurred for the past two months and she finally could not take it anymore. Endoscopy confirmed a duodenal ulcer. Patient Case What endoscopic test could be used to detect H. pylori? 1. Antibody detection 2. Urea breath test 3. Histology 4. Fecal antigen test 16

Patient Case A biopsy was performed that revealed H. pylori.. Is an H. pylori eradication therapy regimen appropriate for HP? 1. Yes 2. No Patient Case You discover HP has a PCN allergy. What drug therapy would you recommend if you desired increased patient compliance? 1. Clarithromycin, metronidazole, PPI 2. Clarithromycin, amoxicillin, PPI 3. BSS, tetracycline, clarithromycin, PPI 4. BSS, tetracycline, metronidazole, PPI 17

Patient Case Which regimen would likely be the least expensive for the patient? 1. Clarithromycin, metronidazole, H 2 B 2. Clarithromycin, amoxicillin, PPI 3. BSS, tetracycline, clarithromycin, H 2 B 4. Levofloxacin, amoxicillin, PPI Summary H. pylori is a common microorganism that has an association with PUD It has multiple virulence factors that promote its survival in the stomach s acidic environment It should be treated in all patients with active ulcer disease 18

Summary Goal of therapy is permanent eradication Treatment regimens include antibiotics and antisecretory agents Adverse effects, compliance and cost should oud be considered sde ed when initiating therapy 19